The company has a market capitalization of $92,920.00, a PE ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13.
A number of large investors have recently bought and sold shares of GILD. About 6.08 million shares traded. About shares traded. Novocure Ltd (NASDAQ:NVCR) has declined 0.43% since November 14, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.
Parnassus Investments decreased National Oilwell Varco Inc. (MA) by 8.57% based on its latest 2017Q2 regulatory filing with the SEC. Penserra Capital Management LLC increased its holdings in shares of Gilead Sciences by 9.5% during the 1st quarter. The stock declined 2.37% or $1.72 reaching $71.12 per share. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Mastercard Inc (NYSE:MA) has risen 24.16% since November 14, 2016 and is uptrending. It has outperformed by 19.53% the S&P500. The stock of Gilead Sciences, Inc. Investment Centers of America Inc. boosted its stake in shares of Gilead Sciences by 7.2% in the 1st quarter. In the last earnings report the EPS was $8.79 with 1.31B shares presently outstanding. ABT's profit will be $1.27 billion for 18.82 P/E if the $0.73 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth. Stoneridge Investment Partners LLC acquired a new position in Gilead Sciences in the first quarter worth about $4,813,000.
Institutions own 75.10% of Gilead Sciences, Inc. Q3 Earnings Drop 19%" on October 26, 2017, also Finance.Yahoo.com with their article: "Gilead Sciences Inc. Gilead Sciences's dividend payout ratio (DPR) is 23.66%. The Washington-based Cornerstone has invested 0.19% in Gilead Sciences, Inc. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. Its down 0.75, from 1.63 in 2017Q1. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00.
NCAA reverses decision, NC State's Braxton Beverly eligible to play
Scott Tompsett, Beverly's attorney, released a state that said the freshman is "absolutely thrilled" by the NCAA's decision. State had to file new information which wasn't initially available in order for the decision to be reconsidered.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Ferguson Wellman Cap Mngmt, Oregon-based fund reported 56,048 shares. They expect $0.39 earnings per share, up 2.63% or $0.01 from last year's $0.38 per share. Ubs Asset Management Americas Inc has 0% invested in Gilead Sciences, Inc. Decreases Position in Gilead Sciences, Inc. With the existing current ratio, Gilead Sciences, Inc.is more than equipped to confront its liabilities with its assets. Hutchin Hill Capital LP reported 0.24% of its portfolio in Abbott Laboratories (NYSE:ABT). 343,686 are held by Rothschild Asset Mngmt. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/14/gilead-sciences-inc-gild-downgraded-by-argus-to-hold.html. (NASDAQ:GILD). Signaturefd Ltd Liability Corp invested in 0.05% or 4,844 shares.
MFA Financial, Inc., a U.S. based Company, belongs to Financial sector and REIT - Diversified industry. (NASDAQ:GILD). State Board Of Administration Of Florida Retirement Sys has 0.37% invested in Gilead Sciences, Inc. Therefore 60% are positive. Gabelli reiterated a "buy" rating on shares of Gilead Sciences in a report on Friday, September 23rd. The firm has "Buy" rating by Oppenheimer given on Tuesday, September 26. (NASDAQ:GILD) has "Market Perform" rating given on Friday, December 4 by Wells Fargo. Robert W. Baird restated an "outperform" rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has "Hold" rating by Jefferies on Friday, October 27. In this case performance of tends to percentage rate of return for a stock for a given time frame. The firm earned "Buy" rating on Monday, November 14 by Stifel Nicolaus. (NASDAQ:GILD) on Wednesday, February 3 with "Overweight" rating. It improved, as 78 investors sold Gilead Sciences, Inc. shares while 538 reduced holdings. 102 funds opened positions while 441 raised stakes. Vestor Capital Limited Liability Co accumulated 37,485 shares or 1.11% of the stock. 6,930 are owned by Williams Jones And Assoc Ltd Liability Corporation. Salient Cap Advisors Lc owns 45,329 shares. Meridian Counsel holds 0.92% or 21,847 shares in its portfolio. Patters in insider activity can help analysts formulate an outlook for a stock. The Premier Asset Managment Llc holds 11,450 shares with $810,000 value, down from 162,781 last quarter. 552 shares valued at $26,482 were sold by Watkin Jared on Thursday, June 15. Northwest Investment Counselors Ltd Llc reported 27,361 shares or 0.6% of all its holdings. Strategic Llc has invested 0.44% in Mastercard Inc (NYSE:MA). Institute For Wealth Limited Liability Company stated it has 0.06% in Abbott Laboratories (NYSE:ABT). Paradigm Cap Mgmt Incorporated invested 0.02% of its portfolio in Abbott Laboratories (NYSE:ABT). The stock declined 3.09% or $2.25 reaching $70.6 per share.
Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24. Among active positions in the latest quarter, 707 holders increased their positions by a total of 72.51 million shares, 755 holders decreased the positions by a total of 68.29 million shares, and 164 holders held their positions.